4.6 Article

Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis

Journal

CARCINOGENESIS
Volume 35, Issue 5, Pages 1078-1083

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgu005

Keywords

-

Categories

Funding

  1. Intramural Research Program of the National Institutes of Health, National Cancer Institute

Ask authors/readers for more resources

Using a novel murine model, we demonstrate that silicotic inflammation increases susceptibility to lung cancer initiated by exposure to NNK, a potent carcinogen in cigarettes. Cancer susceptibility is reduced to background by blocking this inflammation through treatment with immunosuppressive oligonucleotides.Silicosis is an inflammatory lung disease induced by the inhalation of silica-containing dust particles. There is conflicting data on whether patients with silicosis are more susceptible to lung cancer induced by cigarette smoke. To examine this issue experimentally, a model was developed in which one of the most abundant and potent carcinogens present in cigarette smoke [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)] was administered to mice at the peak of silica-induced pulmonary inflammation. Results show that the incidence of lung tumors in silicotic mice treated with NNK was significantly increased compared with mice exposed to silica or NNK alone. Synthetic oligonucleotides (ODN) containing repetitive TTAGGG motifs can block pathologic inflammation. We therefore examined whether treatment with these suppressive (Sup) ODN could block silica-induced pulmonary inflammation and thereby reduce susceptibility to lung cancer. Results show that Sup (but not control) ODN inhibit pulmonary fibrosis and other inflammatory manifestations of chronic silicosis. Of greater import, Sup ODN reduced lung tumor incidence and multiplicity in silicotic mice exposed to NNK. These findings establish an experimental model for examining the role of silicotic inflammation in cancer susceptibility and demonstrate that Sup ODN represent a novel therapy for chronic silicosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available